En Carta Diagnostics, a Paris-based DeepTech startup developing a new generation of molecular diagnostics for use at home, has announced the first closing of €5 million in financing. This closing includes €3 million in equity led by Blue Forest Ventures with participation from Ring Capital and existing investors CentraleSupélec Venture,
Rahul Raj
En Carta Diagnostics, a Paris-based DeepTech startup developing a new generation of molecular diagnostics for use at home, has announced the first closing of €5 million in financing.
This closing includes €3 million in equity led by Blue Forest Ventures with participation from Ring Capital and existing investors CentraleSupélec Venture, 50 Partners Health, and a group of business angels. It also includes €2 million in non-dilutive financing from Bpifrance and other partners. In May 2024, the company secured €1.5 million in pre-Seed funding, led by CentraleSupélec Venture.
“This first closing brings us closer to our mission of transforming access to testing. By enabling patients to perform reliable molecular tests wherever they are, we can support earlier diagnosis, improve patient outcomes, and help relieve pressure on healthcare systems,” said Guillaume Horreard, co-founder and CEO, En Carta Diagnostics.
Founded in 2022 by Horreard and Margot Karlikow, En Carta Diagnostics is developing a new generation of home molecular diagnostics, combining the accuracy of a laboratory PCR with the simplicity of a rapid test.
The company states that its proprietary platform is designed to make high-performance molecular diagnostics accessible where the patient is, without the need for laboratory infrastructure.
The scale-up is tackling Lyme disease, the most prevalent vector-borne disease in the Northern Hemisphere, with 1.2 million cases annually. This disease is caused by Borrelia bacteria and is transmitted to humans through tick bites. The company notes that its incidence is increasing alarmingly at 22.5% per year, according to the CDC (Centres for Disease Control and Prevention).
En Carta claims that it was founded to solve exactly that problem, developing a molecular diagnostic product as simple to use as a rapid test, as precise as a laboratory PCR, and delivering a result in 30 minutes, at home.
It highlights that its technology is a rapid Point-of-Need molecular diagnostic platform, in an affordable cassette format, exhibiting high precision through a technology underpinned by more than ten years of intensive research.
“It uses aptamers, capable of binding with high affinity and specificity to a predetermined target. This ‘signature’ can be programmed to detect any genetic, pathogenic or veterinary indication, opening an extensive range of applications,” En Carta explained.
The company is now focused on bringing its technology to market at scale, starting with early Lyme disease detection and expanding into STI screening.
En Carta also revealed that it has achieved its first-in-human and is running two clinical trials for its flagship product for the early detection of Lyme: in Boston (USA) and in Bialystock (Poland).
In January 2026, it received the FDA Breakthrough Device Designation. This designation grants En Carta an accelerated regulatory pathway to the US market. It has also entered into a co-development and commercialisation agreement with AAZ, a leading French company specialising in self-tests and rapid diagnostic tests.
The agreement represents a €13 million commercial partnership, combining financial commitment with clinical development. The objective is to market a new generation of rapid molecular tests for chlamydia and gonorrhoea in Europe, with committed volumes of several million units over five years.
“From FDA Breakthrough Designation to a €13 million commercial partnership, and now €5 million in financing, En Carta is delivering. Our next milestone is getting our two products, a rapid molecular diagnostic for Borrelia, the bacteria responsible for Lyme disease, and an STI screening test, into the hands of patients and clinicians across Europe and the US,” added Horreard.
With this capital, the company plans to advance regulatory certification of its molecular testing solutions in Europe and the US, supported by its recent FDA Breakthrough Device Designation and progression along an accelerated regulatory pathway. It also aims to boost industrialisation at scale, through a fabless model in partnership with Circum Medical to produce the hardware of the product, enabling cost-efficient, high-volume manufacturing.
And finally, it intends to accelerate the commercial launch and market expansion, starting with early Lyme disease detection and followed by additional applications such as STI screening.
